Innovation Program

Finding Innovative Solutions to Complex Challenges.

We are committed to accelerating microbiome research to develop new applications, methods, and technology to improve human health. We firmly believe that innovative health solutions can be identified and implemented strategically through cooperation and creative thinking.

This belief has fostered the implementation of our Innovation Program, which is dedicated to promoting innovative research aimed at understanding how dietary and nutritional interventions with potential or demonstrated probiotics affect the host and gastrointestinal microbiota, in the broad context of maintaining general wellness and health in humans.

Under the Innovation Program umbrella, LHS has recently held its first national funding competition in collaboration with Mitacs. This funding opportunity was created to stimulate innovative research in the field of probiotics for human health applications. The goals of the LHS Innovation Grant competition were to create opportunities for new sustainable partnerships with researchers across Canada, to provide training opportunities for students, and to foster breakthrough research.


LHS Innovation Grant 2019 Winner Announcement.

We wish to thank all those who have applied to this first edition of the LHS Innovation Grant – Spring 2019.

We are pleased to announce that the winner of the LHS Innovation Grant 2019 is Angus McQuibban, associate professor in the department of biochemistry at the University of Toronto.

Angus McQuibban did his PhD at the University of British Columbia, and his post- doctoral fellowship at the MRC-LMB in Cambridge, UK. The McQuibban lab is studying  the fundamental mechanisms of mitochondrial quality control pathways and  how they impinge on human disease.  Dr McQuibban’s work has pioneered both  cellular and animal models of mitochondrial dysfunction to not only understand molecular mechanisms of disease but to also test potential therapeutic approaches in neurodegeneration. His contributions to this field have been greatly recognized – Dr McQuibban and his collaborators have recently been awarded a $2.3-million grant from Genome Canada to develop drugs for Parkinson’s disease.


Once again, we wish to thank all who have applied; we are looking forward to launching our next LHS Innovation Grant competition.

Stay tuned.


The LHS Innovation Grant – Rules and instructions.

The Spring 2019 competition is now closed.

Who Can Apply

Full-time faculty members from Canadian post-secondary institutions and their affiliated institutions, including hospitals and research institutes. Applicants must be part of an established research program with the capacity to do research on microbiota and its role in human health and disease. The grant recipient will be required to sign a “Research Grant Agreement” outlining the use of funds, results, ownership and intellectual property, and other applicable restrictions.

Eligible Areas of Research

Investigators working on understanding the role of probiotic interventions for different types of health indications. Innovative studies on novel indications, animal models and/or novel bacterial isolates are strongly encouraged.

Research cannot use commercial probiotic strains except for those owned by Lallemand Health Solutions or publicly available without commercial use restraints. Novel strains isolated by the researcher or other academic labs are acceptable. Research using Genetically Modified Organisms (GMOs) developed by the investigators will also be considered.

Grant Information

This grant will support a project over a period of minimum one to maximum three years, for a maximum amount of $ 80,000 CAD (contingent on budget justifications according to the instructions stipulated in the Application Guideline available during the application period). Only proposals submitted within the competition timeline will be eligible.

Selection Criteria

Applications for the research grant will be reviewed by the Lallemand Health Solutions Research Grant Committee, in consultation with external reviewers. Research applications will be scored based on the following criteria:

  • Innovation and originality: originality of the proposed research question, including novel techniques/methodology, novel animal models, novel microbes as well as the potential for creating new knowledge.
  • Feasibility: feasibility of the research project in terms of proposed budget, time frame, staff, and resources available.
  • Applicant’s Excellence in research: an experience of the applicant including independence, a proven track record of peer-reviewed publications, total research funding, team strength and training of highly qualified personnel.
  • Impact of the research: research question to be addressed and how it contributes to health in Canada and worldwide.

Application Process

  • Applicants must submit a completed Letter of Intent (LOI) form and an updated academic CV within the competition deadline. Please refer to the timeline for more information.
  • Documents composing the Application Package must be merged into a single PDF file and emailed to
  • Applications will be reviewed by the Lallemand Health Solutions Scientific Committee.
  • Selected applicant will be invited to complete and submit a Mitacs application package for the Mitacs peer review process.
  • The winner will be notified after successful completion of the peer review process and the research agreement will be signed.
  • Once the process is completed, the grant recipient will be announced publicly on our website.

Application Package

To be considered for this research grant, please send the following documents packaged into a single PDF file:

  • A completed Letter of Intent form, with accompanying Gantt chart
  • An up-to-date CV that includes a list of publications and grants.

Timeline – The current competition is now closed.

  • Application open:  April 15, 2019
  • Submission deadline:  July 1st, 2019
  • Mitacs application process:  August 15, 2019
  • Winner Announcement:  Announced November 2019
  • Grant start date:  First Quarter, 2020

If you have any questions, please email